Telomir Pharmaceuticals Inc TELO
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-02-09 |
| Shares Out. | 73,620,000 |
| Website | telomirpharma.com/ ↗ |
| Phone | 17863966723 |
| Employees | 5 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.7M |
| Free Cash Flow | -$4.9M |
| Total Assets | $5.4M |
| Total Liabilities | $332,424 |
| Equity | $5.0M |
About Telomir Pharmaceuticals Inc
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Telomir Pharmaceuticals Inc is a publicly traded company under the ticker symbol TELO on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-11-01)